Pregabalin NDC 62135-445

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-445Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0445Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-445-90	62135044590	90 CAPSULE in 1 BOTTLE (62135-445-90)Marketed from Jul 25, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pregabalin
Generic name (nonproprietary): pregabalin
Active ingredients: Pregabalin — 75 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Chartwell RX, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212865
Marketing start: Mar 31, 2020
Listing expires: Dec 31, 2026
DEA schedule: CV
Identifiers: Product ID 62135-445_4361bef4-846b-7589-e063-6294a90a9292SPL ID 4361bef4-846b-7589-e063-6294a90a9292SPL set ID 13d03119-e49b-482e-b5f9-d40dc3f4862eRxCUI 483438, 483440, 483448, 483450UNII 55JG375S6MUPC 0362135447908, 0362135445904, 0362135444907, 0362135446901

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135044590 followed by a unit qualifier and the quantity

Package 62135-0445-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 12, 2025.

Indications (excerpt from the label)

Pregabalin is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury Pregabalin Capsules are indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ) Postherpetic neuralgia (PHN) ( 1 ) Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older ( 1 ) Fibromyalgia ( 1 ) Neuropathic pain associated with spinal cord injury ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212865

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212865
Product	Strength	Form · route	Labeler	Product NDC
Pregabalin	Pregabalin 50 mg/1	CapsuleOral	Chartwell RX, LLC	62135-444
Pregabalin	Pregabalin 100 mg/1	CapsuleOral	Chartwell RX, LLC	62135-446
Pregabalin	Pregabalin 150 mg/1	CapsuleOral	Chartwell RX, LLC	62135-447